For example, intratumoral administration of SD-101, a TLR-9 agonist, with or without Pembrolizumab in oligometastatic prostate cancer patients undergoing radiotherapy is under phase-II investigation (302). The gene discussed is TLR9; the disease is prostate carcinoma.